[ad_1]
David Moss, Chief Financial Officer, told Proactive Investors that the immunology biotechnology group was eager to begin recruiting patients for its Phase 1 trial for the treatment of Alzheimer's disease.
The California-based biotech stock has jumped 20% in recent days after Nasdaq's closing bell commemorates its recent IPO. According to Moss, heightened media attention around the bell ceremony, or maybe the upcoming data on his other drug candidates could help fuel the stock.
Source link
